Dr. Mary Ann Gray was appointed to Juniper’s board of directors in March 2016 and serves as audit committee Chair.
Dr. Gray has more than 20 years of experience in the biotechnology and biopharmaceutical industry. She is currently President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm.
Previously, a Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund, Dr. Gray also covered large- and small-cap biotechnology companies while an equity research analyst at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody. Dr. Gray began her career as a scientist focused on new drug development at Schering-Plough and NeoRx Corporation.
Dr. Gray holds a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.
In addition to Juniper, Dr. Gray also serves on the board of directors of two other public biotechnology companies. She is a director of Galena Biopharma, Inc. (oncology) and Senomyx Inc. (technology). Additionally, Dr. Gray was lead director of Dyax Corp. (pharmaceuticals) until its acquisition by Shire plc in early 2016. two other public biotechnology companies. She served on the boards of Acadia Pharmaceuticals (CNS treatments) and TetraLogic Pharmaceuticals Corporation (oncology and infectious disease therapeutics). At Acadia she served as chair of the audit committee and also served on the compensation committee. Dr. Gray previously served as lead director of Dyax Corp. until its acquisition by Shire plc (specialty biopharmaceuticals) in January 2016. Earlier in her career, Dr. Gray managed pre-clinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute and worked in the hospital laboratory.